Tags

Type your tag names separated by a space and hit enter

Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
Metabolism. 2001 Apr; 50(4):477-80.M

Abstract

The aim of the present study was to investigate the effect of bezafibrate on insulin sensitivity and insulin secretion in 30 non-obese Japanese type 2 diabetic patients with hypertriglyceridemia (serum triglycerides > 150 mg/dL). Insulin sensitivity was measured with homeostasis model assessment insulin resistance (HOMA-IR) proposed by Matthews et al. HOMA-B-cell function, proposed by Matthews et al validated against minimal model-derived insulin secretion, was used to assess pancreatic insulin function. Twenty-two patients were treated with glibenclimide and the rest were treated with diet alone. All patients were treated with bezafibrate (400 mg/d) for 3 months. There were no changes in diet and the dose of any medications used throughout the study. Fasting glucose, insulin, triglycerides, HDL cholesterol, and total cholesterol levels were measured before and after treatment of bezafibrate. After treatment of bezafibrate for 3 months, serum triglyceride levels significantly decreased from 277 +/- 30 to 139 +/- 9 mg/dL (P <.001) and serum HDL cholesterol levels increased significantly from 45 +/- 2 to 52 +/- 2 mg/dL (P =.003). Serum cholesterol level was unchanged during the study (198 +/- 7 v 201 +/- 7 mg/dL, P =.383). Fasting glucose (163 +/- 8 v 139 +/- 6 mg/dL, P =.006) significantly decreased after the treatment with bezafibrate. HbA1c levels decreased, although not statistically significant (7.50 +/- 0.25 v 7.17% +/- 0.19%, P =.147). On the other hand, fasting insulin (9.3 +/- 0.7 v 7.3 +/- 0.5 microU/mL, P =.010) and HOMA-IR (3.61 +/- 0.24 to 2.53 +/- 0.20, P <.001) levels decreased significantly after the treatment with bezafibrate. In contrast, HOMA-B-cell function did not change during the study (41.4 +/- 5.5 v 41.8 +/- 4.7, P =.478). There was no significant difference in body mass index (BMI) levels before and after the therapy (23.0 +/- 0.4 v 23.1 +/- 0.4 kg/m(2), P =.483). From these results, it can be concluded that bezafibrate reduces serum triglycerides, insulin resistance, and fasting blood glucose levels in non-obese Japanese type 2 diabetic patients.

Authors+Show Affiliations

Division of Diabetes, Kansai-Denryoku Hospital, Osaka: Department of Metabolism and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

11288046

Citation

Taniguchi, A, et al. "Effects of Bezafibrate On Insulin Sensitivity and Insulin Secretion in Non-obese Japanese Type 2 Diabetic Patients." Metabolism: Clinical and Experimental, vol. 50, no. 4, 2001, pp. 477-80.
Taniguchi A, Fukushima M, Sakai M, et al. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism. 2001;50(4):477-80.
Taniguchi, A., Fukushima, M., Sakai, M., Tokuyama, K., Nagata, I., Fukunaga, A., Kishimoto, H., Doi, K., Yamashita, Y., Matsuura, T., Kitatani, N., Okumura, T., Nagasaka, S., Nakaishi, S., & Nakai, Y. (2001). Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism: Clinical and Experimental, 50(4), 477-80.
Taniguchi A, et al. Effects of Bezafibrate On Insulin Sensitivity and Insulin Secretion in Non-obese Japanese Type 2 Diabetic Patients. Metabolism. 2001;50(4):477-80. PubMed PMID: 11288046.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. AU - Taniguchi,A, AU - Fukushima,M, AU - Sakai,M, AU - Tokuyama,K, AU - Nagata,I, AU - Fukunaga,A, AU - Kishimoto,H, AU - Doi,K, AU - Yamashita,Y, AU - Matsuura,T, AU - Kitatani,N, AU - Okumura,T, AU - Nagasaka,S, AU - Nakaishi,S, AU - Nakai,Y, PY - 2001/4/5/pubmed PY - 2001/5/18/medline PY - 2001/4/5/entrez SP - 477 EP - 80 JF - Metabolism: clinical and experimental JO - Metabolism VL - 50 IS - 4 N2 - The aim of the present study was to investigate the effect of bezafibrate on insulin sensitivity and insulin secretion in 30 non-obese Japanese type 2 diabetic patients with hypertriglyceridemia (serum triglycerides > 150 mg/dL). Insulin sensitivity was measured with homeostasis model assessment insulin resistance (HOMA-IR) proposed by Matthews et al. HOMA-B-cell function, proposed by Matthews et al validated against minimal model-derived insulin secretion, was used to assess pancreatic insulin function. Twenty-two patients were treated with glibenclimide and the rest were treated with diet alone. All patients were treated with bezafibrate (400 mg/d) for 3 months. There were no changes in diet and the dose of any medications used throughout the study. Fasting glucose, insulin, triglycerides, HDL cholesterol, and total cholesterol levels were measured before and after treatment of bezafibrate. After treatment of bezafibrate for 3 months, serum triglyceride levels significantly decreased from 277 +/- 30 to 139 +/- 9 mg/dL (P <.001) and serum HDL cholesterol levels increased significantly from 45 +/- 2 to 52 +/- 2 mg/dL (P =.003). Serum cholesterol level was unchanged during the study (198 +/- 7 v 201 +/- 7 mg/dL, P =.383). Fasting glucose (163 +/- 8 v 139 +/- 6 mg/dL, P =.006) significantly decreased after the treatment with bezafibrate. HbA1c levels decreased, although not statistically significant (7.50 +/- 0.25 v 7.17% +/- 0.19%, P =.147). On the other hand, fasting insulin (9.3 +/- 0.7 v 7.3 +/- 0.5 microU/mL, P =.010) and HOMA-IR (3.61 +/- 0.24 to 2.53 +/- 0.20, P <.001) levels decreased significantly after the treatment with bezafibrate. In contrast, HOMA-B-cell function did not change during the study (41.4 +/- 5.5 v 41.8 +/- 4.7, P =.478). There was no significant difference in body mass index (BMI) levels before and after the therapy (23.0 +/- 0.4 v 23.1 +/- 0.4 kg/m(2), P =.483). From these results, it can be concluded that bezafibrate reduces serum triglycerides, insulin resistance, and fasting blood glucose levels in non-obese Japanese type 2 diabetic patients. SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/11288046/Effects_of_bezafibrate_on_insulin_sensitivity_and_insulin_secretion_in_non_obese_Japanese_type_2_diabetic_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(01)62044-4 DB - PRIME DP - Unbound Medicine ER -